Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORAb-003 in Platinum-Sensitive Epithelial Ovarian Cancer First Relapse
2006-003580-31Phase 2Completed
- Sponsor
- Morphotek
- Start
- Dec 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of farletuzumab in epithelial ovarian cancer (EOC), sponsored by Morphotek. Primary endpoints: CA 125 response and Objective tumor response. Started Dec 2006; status: completed.
02
Drugs
farletuzumab
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2006-003580-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003580-31.